Advancing the Future of Biotech
We are a privately held, early-stage biotechnology corporation focused on developing next-generation therapeutics and platforms. By combining rigorous scientific validation with an aggressive intellectual property strategy, we are positioned to address massive unmet needs in the wildlife and animal contraception and pathogen defense sector.
Investment Highlights
-
- Corporate Structure: Formed as a Delaware C-Corporation, optimized for venture capital and institutional scale.
-
- Proprietary IP Pipeline: Our foundational technology is backed by a robust portfolio of pending patents and exclusive trade secrets.
-
- Capital Efficiency: We operate a lean, milestones-driven R&D model designed to maximize the velocity of seed capital. We do not invest in brick and mortar or expensive laboratory equipment. Instead we contract out our production and testing to ensure high velocity and consistent production standards.
Seed Round Objectives
We are currently opening conversations for our seed funding round. Capital from this round will be directly deployed into high-impact operational and regulatory milestones:
-
- Preclinical Validation: Advancing our lead assets through in vitro and in vivo proof-of-concept studies.
-
- IP Expansion: Broadening our global patent estate to fortify our competitive moat.
-
- Team Scaling: Attracting key scientific and regulatory experts to accelerate time-to-market.
-
- Contract Production: Engaging top of the line contract production companies to produce and package our product lines.
Access the Investor Data Room
To protect our intellectual property, specific details regarding our patent portfolio, pipeline timelines, and pitch deck are reserved for qualified, accredited investors under a non-disclosure agreement (NDA). If you do not desire to execute a non-disclosure agreement, we are more than happy to discuss our projects and timeline. Once you have a clear picture of our portfolio, the highly defensible IP moat, and the value of the potential market and speed to scale, we are certain you will want to engage further with us in more detail under an agreement.
If you are an accredited investor or venture partner interested in reviewing our investment thesis, please contact our executive team.
Request Investor Information
Corporate HQ: Steinhatchee, Florida
Direct Contact: CEO@sawyerboone.com